Featured image of the article A look back at mRNA patenting activity for 2023.

A look back at mRNA patenting activity for 2023

SOPHIA ANTIPOLIS, France – January 16, 2024 │ The last quarterly report for the 2023 Therapeutic mRNA patent monitor is now available! This report covers all aspects of mRNA design, delivery, manufacturing, storing, mRNA-based vaccines, and mRNA-based therapeutics. As we leave behind another year, we look back on the mRNA therapeutic patenting activity! Q4 2023[…]

mRNA Competitive landscape monitoring: A patent perspective – Poster

SOPHIA ANTIPOLIS, France – November 15, 2023 │ KnowMade’s Therapeutic mRNA Patent Monitor was presented at the 11th mRNA health conference in Berlin (October 31 to November 2, 2023) through the poster N°49 (High resolution PDF download here). Abstract Therapeutic mRNA, which became widely known as vaccine against COVID-19, are expected to be applicated to[…]

ReNAgade Therapeutics unveiled new LNPs for delivering mRNA to extra-hepatic tissues: Patent analysis on its proprietary ionizable lipids

SOPHIA ANTIPOLIS, France – November 06, 2023 │ReNAgadeTherapeutics, a company founded in 2021 and based in Cambridge, presented preclinical data demonstrating a new and proprietary method of delivering mRNA to extra-hepatic tissues in non-human primate using lipid nanoparticles (LNPs) at the 11th International mRNA Health Conference, taking place from October 31 to November 2, 2023[…]

Q3 2023 Therapeutic mRNA patent monitor report: focus on mRNA modifications for an improved efficiency

SOPHIA ANTIPOLIS, France – October 25, 2023 │ The quarterly report for the Q3 2023 Therapeutic mRNA patent monitor is now available! This report covers all aspects of mRNA design, delivery, manufacturing, storing, mRNA-based vaccines, and mRNA-based therapeutics. Let’s focus on an aspect of mRNA design that that ended up in a Nobel prize! mRNA[…]